Trial Profile
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Sepantronium bromide (Primary) ; Docetaxel
- Indications Malignant melanoma
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 04 Dec 2012 Planned number of patients changed from 69 to 72 as reported by EudraCT.
- 31 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jul 2012 Additional trial location (France) added as reported by European Clinical Trials Database.